Rhabdomyolysis is a syndrome caused by injury to skeletal muscle and involves leakage of large quantities of potentially toxic intracellular contents into plasma. Its final common pathway may be a disturbance in myocyte calcium homeostasis.
Myoglobin is an important myocyte compound released into plasma (see the image below). After muscle injury, massive plasma myoglobin levels exceed protein binding (of haptoglobin) and can precipitate in glomerular filtrate. Excess myoglobin may thus cause renal tubular obstruction, direct nephrotoxicity (ischemia and tubular injury), intrarenal vasoconstriction, and acute kidney injury (AKI). [1, 2, 3]
See Heat Illness: How To Cool Off Hyperthermic Patients, a Critical Images slideshow, for tips on treatment options for patients with heat-related illness.
The classic triad of rhabdomyolysis comprises the following:
In practice, however, presentation varies considerably. Additional nonspecific symptoms include fever, nausea, and vomiting.
In most cases, the history reflects the inciting cause (though in some, it is nonspecific and thus diagnostically unreliable). Possible causes include the following:
Alcohol use and resultant unresponsiveness
Illicit drug use
Use of prescribed medications
Initial physical findings may be nonspecific. The following may be noted:
Muscular pain and tenderness
Decreased muscle strength
Soft tissue swelling
Skin changes consistent with pressure necrosis
Hyperthermia, hypothermia, and electrical injuries
Crush injuries or deformities in long bones
Complications of rhabdomyolysis include the following:
Acute kidney injury (AKI) and renal failure
Disseminated intravascular coagulation (DIC, a late complication)
See Presentation for more detail.
Laboratory tests that may be useful include the following:
Complete blood count (CBC), including hemoglobin, hematocrit, and platelets
Prothrombin time (PT)
Activated partial thromboplastin time (aPTT)
Lactate dehydrogenase (LDH)
Cardiac troponin I
Creatine kinase (most reliable and sensitive indicator of muscle injury)
Imaging studies generally play only a small diagnostic role but may be considered in particular settings, as follows:
Radiography (suspected fracture)
Computed tomography (CT) of the head (altered sensorium, significant head trauma, seizure, neurologic deficits of unknown origin)
Magnetic resonance imaging (MRI; assessment of myopathy)
Other tests that may be considered include the following:
Measurement of compartment pressures
Immunoblotting, immunofluorescence, and genetic studies
See Workup for more detail.
Medical management of rhabdomyolysis includes the following:
Assessment of the ABCs (A irway, B reathing, C irculation)
Identification and correction of the inciting cause (eg, trauma, infection, or toxins)
Fluid resuscitation, initiated as soon as possible
Institution of measures to prevent of AKI and acute renal failure (ARF) – Urinary alkalization, mannitol, loop diuretics
Correction of electrolyte, acid-base, and metabolic abnormalities
Other medical treatment measures may include the following:
Dialysis, if indicated
Use of free-radical scavengers and antioxidants (clinical utility remains unclear)
Discontinuance of any inciting myotoxic agents
Depending on the cause of rhabdomyolysis, surgical care may be necessary, as follows:
When intracompartmental pressure exceeds 30 mm Hg, a fasciotomy is advocated
Limb fractures may call for surgical and orthopedic treatment
Lifestyle-related treatment measures may be considered, as follows:
Dietary modification to help address metabolic disorders or inborn errors of metabolism
Avoidance of strenuous activities if such activities cause recurrent myalgias, myopathy, or rhabdomyolysis
Maintenance of proper hydration during athletic exertion
Prompt attention to indicators of heat exhaustion during hot and humid conditions
Rhabdomyolysis (literally, “dissolution of skeletal muscle”) is a syndrome caused by injury to skeletal muscle and involves leakage of large quantities of potentially toxic intracellular contents into plasma.  First described in the victims of crush injury during World War II,  it is a final pathway of diverse processes and insults.  The final common pathway of rhabdomyolysis may be a disturbance in myocyte calcium homeostasis. 
In adults, rhabdomyolysis is characterized by the triad of muscle weakness, myalgias, and dark urine.  In many children with this condition, however, all 3 symptoms may not be seen together. [8, 9] Myalgias and generalized muscle weakness are the most common presenting symptoms. Life-threatening renal failure and disseminated intravascular coagulation (DIC) are dreaded complications that appear to be more common in adults. 
Rhabdomyolysis has many etiologies and is often multifactorial in adult patients. Infection and inherited disorders appear to be the most prevalent etiologies in children.  The physician must be alert to the diagnosis of rhabdomyolysis and to its subtle presentation to prevent acute renal failure. Sensitive laboratory markers of myocyte injury include elevated plasma creatine kinase (CK) levels (often in excess of 4- to 5-fold the upper limit of normal). 
Management of rhabdomyolysis consists primarily of correction of fluid and electrolyte anomalies. With adequate supportive measures, the clinical outcome of rhabdomyolysis is often favorable in children.  Recurrent episodes of rhabdomyolysis, especially in children, may indicate underlying defects of muscle structure or metabolism. 
The multiplicity of potential causes of rhabdomyolysis notwithstanding, the final common denominator appears to be disruption of the sarcolemma and release of intracellular myocyte components. Mechanisms of cell destruction in rhabdomyolysis include cellular membrane injury, muscle cell hypoxia, adenosine triphosphate (ATP) depletion, electrolyte disturbances that cause perturbation of sodium-potassium pumps, and generation of oxidative free radicals. 
The sarcolemma, a thin membrane that encloses striated muscle fibers, contains numerous pumps that regulate cellular electrochemical gradients. The intercellular sodium concentration is normally maintained at 10 mEq/L by a sodium-potassium adenosine triphosphatase (Na/K-ATPase) pump located in the sarcolemma. 
The Na/K-ATPase pump actively transports sodium from the interior of the cell to the exterior. As a result, the interior of the cell is more negatively charged than the exterior because positive charges are transported across the membrane. The gradient pulls sodium to the interior of the cell in exchange for calcium through a protein carrier exchange mechanism. In addition, an active calcium exchanger promotes calcium entry into the sarcoplasmic reticulum and mitochondria.
These processes depend on ATP as a source of energy. ATP depletion appears to be the end result of most causes of rhabdomyolysis. This depletion disrupts cellular transport mechanisms and alters electrolyte composition. 
An increase in intracellular calcium levels results in hyperactivity of proteases and proteolytic enzymes and generation of free oxygen radicals. These enzymes and substances increasingly degrade myofilaments and injure membrane phospholipid with leakage of intracellular contents into plasma. These contents include potassium, phosphate, CK, urate, and myoglobin.
Excess fluid may also accumulate within affected muscle tissue. The action of phospholipases in insect and snake venom may cause hemolysis, muscle damage, endothelial necrosis, rhabdomyolysis, and acute kidney injury (AKI).  Additionally, muscle damage is amplified by infiltration of activated neutrophils. An inflammatory cascade and reperfusion injury sustains muscle damage and degeneration. [14, 11]
Myoglobin is an important myocyte compound released into plasma (see the image below). After muscle injury, massive plasma myoglobin levels exceed protein binding (of haptoglobin) and can precipitate in glomerular filtrate. Excess myoglobin may thus cause renal tubular obstruction, direct nephrotoxicity (ischemia and tubular injury), intrarenal vasoconstriction, and acute kidney injury (AKI; see below). [1, 2, 3]
AKI is believed to be due to decreased extracellular volume, which results in renal vasoconstriction. It is also believed to be due to ferrihemate, which is formed from myoglobin at a pH level of 5.6 or less. Ferrihemate produces free hydroxy radicals and causes direct nephrotoxicity, often through lipid peroxidation. These heme-proteins may enhance vasoconstriction through interactions with nitric oxide (NO) and endothelin receptors. The roles of cytokines in this process have also been discussed. 
Renal vasoconstriction and ischemia deplete tubular ATP formation and enhance tubular cell damage. Myoglobin precipitation in renal tubules causes formation of obstructive casts. AKI rarely occurs in patients with chronic myopathies unless it is triggered by a second inciting event.  The risk of renal injury is low when initial CK levels are lower than 15,000-20,000 U/L. Lower CK levels may lead to renal injury in patients with sepsis, dehydration, or acidosis. 
Gastrointestinal (GI) ischemia is common in patients with fluid and electrolyte imbalances. This ischemia leads to endotoxin absorption, cytokine production, and perpetuation of the systemic inflammatory response.
Trauma and muscle compression are believed to cause rhabdomyolysis through direct injury to muscle, resulting in disruption of the sarcolemma and direct leakage of cell contents. [1, 14] Occlusion of muscular vessels due to thromboemboli, traumatic injury, or surgical clamping may lead to rhabdomyolysis if muscle tissue ischemia is prolonged. This is the leading cause of rhabdomyolysis in children aged 9-18 years, according to one review. 
Orthopedic trauma, including compartment syndromes and fractures, may result in rhabdomyolysis. Such trauma commonly occurs in traffic and occupational accidents. Orthopedic injuries in natural disasters (eg, earthquakes) are compounded by immobilization, hypovolemia, and significant rates of rhabdomyolysis.
Trauma-related events that are particularly likely to lead to rhabdomyolysis include the following:
High-voltage electrical injury due to lightning strikes or accidental exposures 
Prolonged immobilization (eg, after excess alcohol or drug consumption, after an unwitnessed incapacitating stroke, or after prolonged surgical procedures)
Researchers believe that viruses may cause rhabdomyolysis by directly attacking the muscle and generating muscle-specific toxin. While infections may lead to only 5% of adult rhabdomyolysis events, viral-induced myositis appears to be the most common etiology for rhabdomyolysis in children younger than age 9 years. [6, 18] Viral infectious disease agents that may cause rhabdomyolysis include the following  :
Influenza types A and B (most common)
Herpes simplex virus
West Nile virus 
Legionella is the bacterium classically associated with rhabdomyolysis in adult patients. The pathogenesis is believed to be due to direct invasion and toxic degeneration of muscle fibers. However, any microbe that causes sepsis and toxic shock may potentiate muscle damage and necrosis. Malaria due to Plasmodium falciparum is a common cause of rhabdomyolysis outside the United States. Bacterial infectious agents that may cause rhabdomyolysis include the following  :
Group B beta-hemolytic streptococci
Salmonella species 
Legionella species 
Mycoplasma species 
Leptospira species 
Fungal infectious agents that may cause rhabdomyolysis include the following  :
Certain genetic muscle defects are believed to cause rhabdomyolysis because of the muscle’s inability to use ATP appropriately. Because of inadequate ATP production, the mismatch of energy supply and demand may result in the disruption of cell membranes during exercise.
Any inherited condition that impairs energy delivery to muscle may cause rhabdomyolysis.  Such conditions include diseases of glucose, glycogen, fatty acid, or nucleoside metabolism. [29, 30] These disorders often appear in childhood and should be suspected in recurrent cases of myoglobinuria, rhabdomyolysis, or both. Physical exertion and fasting states may exacerbate muscle damage in these disorders. [12, 31]
Electrolyte derangement such as hypophosphatemia is believed to cause rhabdomyolysis because of the resulting shortage of phosphate necessary for the production of ATP. Hypokalemia creates a negative potassium balance, which causes rhabdomyolysis.  Hypokalemia due to dehydration and exercise may also cause rhabdomyolysis.  Hyponatremia  and hypernatremia have also been associated with rhabdomyolysis.
Hypothyroidism, hyperthyroidism,  diabetic ketoacidosis and nonketotic hyperosmolar diabetic coma have been associated with rhabdomyolysis. Metabolic and genetic deficiencies that may cause rhabdomyolysis include the following:
Glycogen phosphorylase deficiency type V (ie, McArdle disease)
Phosphoglycerate mutase deficiency
Phosphoglycerate kinase deficiency (PGK)
Carnitine palmityl transferase deficiency (CPT I and II)
Mitochondrial respiratory chain enzyme deficiencies (including deficiencies of the acyl-CoA dehydrogenase [ACAD] family of proteins)
Myoadenylate deaminase deficiency
Case reports of rhabdomyolysis related to anesthesia in children are believed to be due to underlying muscle disease. Conditions that lead to hyperthermia-related rhabdomyolysis include neuroleptic malignant syndrome and malignant hyperthermia. 
A pediatric case series described an often fatal, malignant, hyperthermia-like syndrome characterized by rhabdomyolysis during initial presentation of diabetes mellitus in adolescent males.  Although these cases resembled hyperglycemic hyperosmolar nonketotic syndrome (HHNS), patient courses were marked by rhabdomyolysis and cardiovascular instability. The underlying etiology of this catastrophic presentation of adolescent diabetes mellitus is unclear.
Rheumatologic disorders which rarely cause rhabdomyolysis include polymyositis, dermatomyositis, Sjögren syndrome, mixed connective tissue disease and systemic lupus erythematosus. Rhabdomyolysis also has been reported in patients with sickle cell anemia and has mistakenly been identified as a pain crisis.
A study by Vivante et al used whole exome sequencing in a cohort of 21 unrelated families with rhabdomyolysis and detected causative mutations in candidate genes in 43% of the families. The study also reported disease-causing mutations in eight of 58 genes (fatty acid metabolism disorders, glycogen metabolism disorders, abnormal skeletal muscle relaxation disorders, and purine metabolism disorders). 
A study by Nelson et al found that sickle cell trait was associated with a higher risk of exertional rhabdomyolysis (similar to the risk associated with tobacco use) among 47,944 soldiers who had undergone testing for hemoglobin AS. 
Any drug that impairs skeletal muscle ATP production or increases energy requirements may cause rhabdomyolysis.  Direct drug-induced sarcolemmal injury is often mediated by activation of phospholipase A.
Toxin-mediated rhabdomyolysis may result from substance abuse, in both adults and adolescents, including abuse of the following:
Lysergic acid diethylamide (LSD)
Ethanol causes metabolic derangement through direct toxicity and disruption of the muscle blood supply by immobilization. Ethanol abuse may cause hypophosphatemia and hypokalemia, which are additive causes of rhabdomyolysis. Alcohol withdrawal, along with delirium tremens and seizures, may be additional factors. Patients who overdose on narcotics and sedative-hypnotics often remain immobilized for extended periods and may have pressure necrosis that results in rhabdomyolysis. Cocaine can directly damage muscle tissue by causing vasoconstriction and tissue ischemia.
Rhabdomyolysis may also result from the use of prescription and nonprescription medications, including the following  :
Antihistamines (particularly in children)
Fibric acid derivatives (eg, bezafibrate, clofibrate, fenofibrate, and gemfibrozil) 
Anesthetic and paralytic agents (the malignant hyperthermia syndrome)
Selective serotonin reuptake inhibitors (the serotonin syndrome)
Phenylpropanolamine (recalled from the US market)
Propofol (continuous infusion) 
According to a retrospective analysis of FDA records (2004-2009),  the most commonly suspected drug exposure in children younger than 10 years was propofol.
Statins, though tolerated by most adult patients, can cause myopathy and, rarely, rhabdomyolysis. [49, 50] They appear to affect ATP production by impairing mitochondrial function. Specific impairments may involve the electron transport chain. Statins may also alter the balance between protein repair and degradation by affecting ubiquitin proteosome pathway gene expression.  Other mechanisms of statin myopathy include depletion of isoprenoids and coenzyme Q10.
Environmental toxins that may cause rhabdomyolysis include the following:
Carbon monoxide 
Hemlock herbs from quail – Rhabdomyolysis after the consumption of quail is well known in the Mediterranean region; it occurs as the result of intoxication by hemlock herbs that the quails consume
Snake venom, spider (eg, black widow spider) venom, hornet venom, and massive envenomations of Africanized honey bees
Exertional activity (eg, marathons, squats, pushups, or sit-ups and other intense repetitive physical exercises)  may cause rhabdomyolysis, especially in untrained individuals. Such events often occur under extremely hot or humid conditions and are related to exertional heat stress and heatstroke. [84, 85] Most of these events occur in military recruits and competitive athletes. Cold exposure in addition to heatstroke is an environmental cause of rhabdomyolysis.  Factors that increase the risk of exertional rhabdomyolysis and renal failure include the following [56, 57, 58] :
Use of nutritional supplements
Sickle cell trait
Rhabdomyolysis as a complication of respiratory failure and status epilepticus or status asthmaticus has been reported.  Whether mechanical ventilation, corticosteroids, or neuromuscular blockade are risk factors in this condition is unclear.  Rhabdomyolysis may occur after other conditions associated with excessive muscular activity, including severe dystonia, acute psychosis, and excessive computer keyboard use or gaming. 
Rhabdomyolysis is a common condition in adult populations and is understudied in pediatrics. [62, 6] The National Hospital Discharge Survey reports 26,000 cases annually.  Most adult cases of rhabdomyolysis are due to abuse of illicit drugs or alcohol, muscular trauma, crush injuries, and myotoxic effects of prescribed drugs. Rhabdomyolysis is found in 24% of adult patients who present to emergency departments (EDs) with cocaine-related conditions.
In a large adult cohort, 60% of cases had multiple factors.  Significant pediatric etiologies include infections, trauma, metabolic conditions, and muscle diseases. In a retrospective review at a tertiary care pediatric center review spanning 10 years, viral myositis accounted for most cases in patients aged 0-9 years, whereas trauma was the leading diagnosis in patients aged 9-18 years. 
The incidence of myoglobin-induced acute kidney injury in adult rhabdomyolysis ranges from 17-35%. This complication was found in 42% of pediatric patients in a small, retrospective cohort study, in 8.7% in a review of nontraumatic causes in children younger than 7 years,  and in only 5% in the larger 10-year review mentioned above. [6, 64] Approximately 28-37% of adult patients require short-term hemodialysis. Rhabdomyolysis is believed to be responsible for 5-20% of all adult cases of acute kidney injury. A comparable figure in children is unavailable.
Large numbers of patients may develop rhabdomyolysis and renal failure during disasters such as earthquakes. Severe crush injuries and delayed extrication of survivors characterize such events. Organizations such as the International Society of Nephrology have implemented measures to support local agencies in providing life-saving dialysis treatments for patients with rhabdomyolysis. 
Rhabdomyolysis is more common in adults, though it may occur in infants, toddlers, and adolescents who have inherited enzyme deficiencies of carbohydrate or lipid metabolism or who have inherited myopathies, such as Duchenne muscular dystrophy and malignant hyperthermia.
The incidence is higher in males than in females, especially in the subgroups of patients with trauma and inherited enzyme deficiencies.
The overall mortality for patients with rhabdomyolysis is approximately 5%; however, the risk of death for any single patient is dependent on the underlying etiology and any existing comorbid conditions that may be present and may be significantly higher in patients with AKI and extremely elevated CPK levels.
Implementation of the treatment modalities currently used (see Treatment) has reduced morbidity and mortality. In a 10-year retrospective pediatric review, only 13 of 191 (6%) of patients died. Of these 13 patients, 9 presented in cardiopulmonary arrest and could not be resuscitated. 
Rapid intervention and appropriate supportive treatment of rhabdomyolysis-related kidney injury and renal failure improve outcomes in traumatic crush injuries. The ability of medical response teams to provide aggressive hydration and dialysis services enhances survival in large-scale natural disasters such as earthquakes. If treatment modalities are implemented early, many patients recover completely.
Educate patients about the causes of rhabdomyolysis and its prevention. Provide genetic counseling for families with inherited muscle enzyme and energy substrate deficiencies. Educate high-school and college athletes about signs of dehydration and heat-related injuries. Advise patients with rhabdomyolysis caused by hyperthermia or inordinate exertion to exercise in moderation, with careful attention to hydration and external methods of cooling.
Advise patients with rhabdomyolysis related to ethanol, recreational drugs, or prescription medications to discontinue use of the offending agent. Refer these patients to a rehabilitation program if necessary.
Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol. 1988 Sep. 255(3 Pt 2):F539-44. [Medline].
Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009 Jul 2. 361(1):62-72. [Medline].
Beetham R. Biochemical investigation of suspected rhabdomyolysis. Ann Clin Biochem. 2000 Sep. 37 ( Pt 5):581-7. [Medline].
Better OS. The crush syndrome revisited (1940-1990). Nephron. 1990. 55(2):97-103. [Medline].
Mannix R, Tan ML, Wright R, Baskin M. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics. 2006 Nov. 118(5):2119-25. [Medline].
Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010 Jun. 48(6):749-56. [Medline].
Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore). 1982 May. 61(3):141-52. [Medline].
Watemberg N, Leshner RL, Armstrong BA, Lerman-Sagie T. Acute pediatric rhabdomyolysis. J Child Neurol. 2000 Apr. 15(4):222-7. [Medline].
Elsayed EF, Reilly RF. Rhabdomyolysis: a review, with emphasis on the pediatric population. Pediatr Nephrol. 2010 Jan. 25(1):7-18. [Medline].
Luck RP, Verbin S. Rhabdomyolysis: a review of clinical presentation, etiology, diagnosis, and management. Pediatr Emerg Care. 2008 Apr. 24(4):262-8. [Medline].
Brumback RA, Feeback DL, Leech RW. Rhabdomyolysis in childhood. A primer on normal muscle function and selected metabolic myopathies characterized by disordered energy production. Pediatr Clin North Am. 1992 Aug. 39(4):821-58. [Medline].
Sitprija V. Animal toxins and the kidney. Nat Clin Pract Nephrol. 2008 Nov. 4(11):616-27. [Medline].
Malinoski DJ, Slater MS, Mullins RJ. Crush injury and rhabdomyolysis. Crit Care Clin. 2004 Jan. 20(1):171-92. [Medline].
Schwengel D, Ludwig S. Rhabdomyolysis and myoglobinuria as manifestations of child abuse. Pediatr Emerg Care. 1985 Dec. 1(4):194-7. [Medline].
Peebles J, Losek JD. Child physical abuse and rhabdomyolysis: case report and literature review. Pediatr Emerg Care. 2007 Jul. 23(7):474-7. [Medline].
Singh U, Scheld WM. Infectious etiologies of rhabdomyolysis: three case reports and review. Clin Infect Dis. 1996 Apr. 22(4):642-9. [Medline].
Nauss MD, Schmidt EL, Pancioli AM. Viral myositis leading to rhabdomyolysis: a case report and literature review. Am J Emerg Med. 2009 Mar. 27(3):372.e5-372.e6. [Medline].
Patel N, Patel N, Espinoza LR. HIV infection and rheumatic diseases: the changing spectrum of clinical enigma. Rheum Dis Clin North Am. 2009 Feb. 35(1):139-61. [Medline].
Wang YM, Zhang Y, Ye ZB. Rhabdomyolysis following recent severe coxsackie virus infection in patient with chronic renal failure: one case report and a review of the literature. Ren Fail. 2006. 28(1):89-93. [Medline].
Pirounaki M, Liatsos G, Elefsiniotis I, Skounakis M, Moulakakis A. Unusual onset of varicella zoster reactivation with meningoencephalitis, followed by rhabdomyolysis and renal failure in a young, immunocompetent patient. Scand J Infect Dis. 2007. 39(1):90-3. [Medline].
Gupta M, Ghaffari M, Freire AX. Rhabdomyolysis in a patient with West Nile encephalitis and flaccid paralysis. Tenn Med. 2008 Apr. 101(4):45-7. [Medline].
Eliasson H, Broman T, Forsman M, Bäck E. Tularemia: current epidemiology and disease management. Infect Dis Clin North Am. 2006 Jun. 20(2):289-311, ix. [Medline].
Antonarakis ES, Wung PK, Durand DJ, Leyngold I, Meyerson DA. An atypical complication of atypical pneumonia. Am J Med. 2006 Oct. 119(10):824-7. [Medline].
Weng WC, Peng SS, Wang SB, Chou YT, Lee WT. Mycoplasma pneumoniae–associated transverse myelitis and rhabdomyolysis. Pediatr Neurol. 2009 Feb. 40(2):128-30. [Medline].
Turhan V, Atasoyu EM, Kucukardali Y, Polat E, Cesur T, Cavuslu S. Leptospirosis presenting as severe rhabdomyolysis and pulmonary haemorrhage. J Infect. 2006 Jan. 52(1):e1-2. [Medline].
Scheuerman O, Wanders RJ, Waterham HR, Dubnov-Raz G, Garty BZ. Mitochondrial trifunctional protein deficiency with recurrent rhabdomyolysis. Pediatr Neurol. 2009 Jun. 40(6):465-7. [Medline].
Korematsu S, Kosugi Y, Kumamoto T, Yamaguchi S, Izumi T. Novel mutation of early, perinatal-onset, myopathic-type very-long-chain acyl-CoA dehydrogenase deficiency. Pediatr Neurol. 2009 Aug. 41(2):151-3. [Medline].
Löfberg M, Jänkälä H, Paetau A, Härkönen M, Somer H. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand. 1998 Oct. 98(4):268-75. [Medline].
Agrawal S, Agrawal V, Taneja A. Hypokalemia causing rhabdomyolysis resulting in life-threatening hyperkalemia. Pediatr Nephrol. 2006 Feb. 21(2):289-91. [Medline].
Knochel JP. Hypophosphatemia and rhabdomyolysis. Am J Med. 1992 May. 92(5):455-7. [Medline].
Strachan P, Prisco D, Multz AS. Recurrent rhabdomyolysis associated with polydipsia-induced hyponatremia – a case report and review of the literature. Gen Hosp Psychiatry. 2007 Mar-Apr. 29(2):172-4. [Medline].
Lichtstein DM, Arteaga RB. Rhabdomyolysis associated with hyperthyroidism. Am J Med Sci. 2006 Aug. 332(2):103-5. [Medline].
Pedrozzi NE, Ramelli GP, Tomasetti R, Nobile-Buetti L, Bianchetti MG. Rhabdomyolysis and anesthesia: a report of two cases and review of the literature. Pediatr Neurol. 1996 Oct. 15(3):254-7. [Medline].
Hollander AS, Olney RC, Blackett PR, Marshall BA. Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males. Pediatrics. 2003 Jun. 111(6 Pt 1):1447-52. [Medline]. [Full Text].
Vivante A, Ityel H, Pode-Shakked B, Chen J, Shril S, van der Ven AT, et al. Exome sequencing in Jewish and Arab patients with rhabdomyolysis reveals single-gene etiology in 43% of cases. Pediatr Nephrol. 2017 Dec. 32 (12):2273-2282. [Medline].
Nelson DA, Deuster PA, Carter R 3rd, Hill OT, Wolcott VL, Kurina LM. Sickle Cell Trait, Rhabdomyolysis, and Mortality among U.S. Army Soldiers. N Engl J Med. 2016 Aug 4. 375 (5):435-42. [Medline].
Coco TJ, Klasner AE. Drug-induced rhabdomyolysis. Curr Opin Pediatr. 2004 Apr. 16(2):206-10. [Medline].
Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006 Jun. 96(6):678-85. [Medline].
Ahn SC. Neuromuscular complications of statins. Phys Med Rehabil Clin N Am. 2008 Feb. 19(1):47-59, vi. [Medline].
Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med. 2011. 50(8):845-53. [Medline].
Frydrychowicz C, Pasieka B, Pierer M, Mueller W, Petros S, Weidhase L. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report. J Med Case Rep. 2017 Jan 4. 11 (1):8. [Medline].
Wrenn KD, Oschner I. Rhabdomyolysis induced by a caffeine overdose. Ann Emerg Med. 1989 Jan. 18(1):94-7. [Medline].
Holoshitz N, Alsheikh-Ali AA, Karas RH. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am J Cardiol. 2008 Jan 1. 101(1):95-7. [Medline].
Hung CF, Huang TY, Lin PY. Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder. Gen Hosp Psychiatry. 2009 Jul-Aug. 31(4):376-8. [Medline].
Ramachandran R, Wierzbicki AS. Statins, Muscle Disease and Mitochondria. J Clin Med. 2017 Jul 25. 6 (8):1047-51. [Medline].
Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004 Dec 1. 292(21):2585-90. [Medline].
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003 Apr 2. 289(13):1681-90. [Medline].
Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. 2005 Dec. 25(12):2560-6. [Medline]. [Full Text].
Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009 Jun 16. 150(12):858-68. [Medline].
Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004 Jul 21. 292(3):331-7. [Medline].
Kao LW, Nañagas KA. Toxicity associated with carbon monoxide. Clin Lab Med. 2006 Mar. 26(1):99-125. [Medline].
Aslam AF, Aslam AK, Vasavada BC, Khan IA. Hypothermia: evaluation, electrocardiographic manifestations, and management. Am J Med. 2006 Apr. 119(4):297-301. [Medline].
Bergeron MF, McKeag DB, Casa DJ, Clarkson PM, Dick RW, Eichner ER, et al. Youth football: heat stress and injury risk. Med Sci Sports Exerc. 2005 Aug. 37(8):1421-30. [Medline].
Hurley JK. Severe rhabdomyolysis in well conditioned athletes. Mil Med. 1989 May. 154(5):244-5. [Medline].
Sinert R, Kohl L, Rainone T, Scalea T. Exercise-induced rhabdomyolysis. Ann Emerg Med. 1994 Jun. 23(6):1301-6. [Medline].
Chen YJ, Chang SH, Yuan A, Huang CH, Lee CC. Rhabdomyolysis after successful resuscitation of a patient with near-fatal asthma. Am J Emerg Med. 2007 Jul. 25(6):736.e3-4. [Medline].
Mehta R, Fisher LE Jr, Segeleon JE, Pearson-Shaver AL, Wheeler DS. Acute rhabdomyolysis complicating status asthmaticus in children: case series and review. Pediatr Emerg Care. 2006 Aug. 22(8):587-91. [Medline].
Song SH, Lee DW, Lee SB, Kwak IS. Rhabdomyolysis caused by strenuous computer gaming. Nephrol Dial Transplant. 2007 Apr. 22(4):1263-4. [Medline].
Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005 Nov. 84(6):377-85. [Medline].
Wu CT, Huang JL, Lin JJ, Hsia SH. Factors associated with nontraumatic rhabdomyolysis and acute renal failure of children in Taiwan population. Pediatr Emerg Care. 2009 Oct. 25(10):657-60. [Medline].
Chamberlain MC. Rhabdomyolysis in children: a 3-year retrospective study. Pediatr Neurol. 1991 May-Jun. 7(3):226-8. [Medline].
Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med. 1988 Jul. 148(7):1553-7. [Medline].
Fernandez WG, Hung O, Bruno GR, Galea S, Chiang WK. Factors predictive of acute renal failure and need for hemodialysis among ED patients with rhabdomyolysis. Am J Emerg Med. 2005 Jan. 23(1):1-7. [Medline].
Li SF, Zapata J, Tillem E. The prevalence of false-positive cardiac troponin I in ED patients with rhabdomyolysis. Am J Emerg Med. 2005 Nov. 23(7):860-3. [Medline].
Baeza-Trinidad R, Brea-Hernando A, Morera-Rodriguez S, Brito-Diaz Y, Sanchez-Hernandez S, El Bikri L, et al. Creatinine as predictor value of mortality and acute kidney injury in rhabdomyolysis. Intern Med J. 2015 May 26. [Medline].
Lappalainen H, Tiula E, Uotila L, Mänttäri M. Elimination kinetics of myoglobin and creatine kinase in rhabdomyolysis: implications for follow-up. Crit Care Med. 2002 Oct. 30(10):2212-5. [Medline].
Young SE, Miller MA, Docherty M. Urine dipstick testing to rule out rhabdomyolysis in patients with suspected heat injury. Am J Emerg Med. 2009 Sep. 27(7):875-7. [Medline].
Salluzzo R, Schwartz M,. Rhabdomyolysis. Emergency Clinical Practice. 4th ed. 1998. 2478-86.
Moratalla MB, Braun P, Fornas GM. Importance of MRI in the diagnosis and treatment of rhabdomyolysis. Eur J Radiol. 2008 Feb. 65(2):311-5. [Medline].
[Guideline] Finnish Medical Society Duodecim. Rhabdomyolysis. EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Apr 12. [Full Text].
Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med. 1990 Mar 22. 322(12):825-9. [Medline].
Iraj N, Saeed S, Mostafa H, Houshang S, Ali S, Farin RF, et al. Prophylactic fluid therapy in crushed victims of Bam earthquake. Am J Emerg Med. 2011 Sep. 29(7):738-42. [Medline].
Gunn VL, Nechyba C, eds. The Harriet Lane Handbook. 16th ed. St Louis, MO: Mosby Elsevier, Inc.; 2002. 45:
Brown CV, Rhee P, Chan L, Evans K, Demetriades D, Velmahos GC. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference?. J Trauma. 2004 Jun. 56(6):1191-6. [Medline].
Sever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. N Engl J Med. 2006 Mar 9. 354(10):1052-63. [Medline].
Thoenes M. Rhabdomyolysis: when exercising becomes a risk. J Pediatr Health Care. 2010 May-Jun. 24(3):189-93. [Medline].
Harding A. New risk score predicts outcome in rhabdomyolysis. Medscape Medical News. September 4, 2013. Available at http://www.medscape.com/viewarticle/810443. Accessed: September 9, 2013.
McMahon GM, Zeng X, Waikar SS. A Risk Prediction Score for Kidney Failure or Mortality in Rhabdomyolysis. JAMA Intern Med. 2013 Sep 2. [Medline].
Scalco RS, Snoeck M, Quinlivan R, Treves S, Laforét P, Jungbluth H, et al. Exertional rhabdomyolysis: physiological response or manifestation of an underlying myopathy?. BMJ Open Sport Exerc Med. Sept 2016. 2:135-145. [Medline].
Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016 Jun 15. 20 (1):135. [Medline].
Marietta Morales De Guzman, MD Associate Professor, Section of Immunology, Allergy and Rheumatology, Department of Pediatrics, Baylor College of Medicine; Clinic Chief, Pediatric Rheumatology Center, Texas Children’s Hospital
Disclosure: Nothing to disclose.
Lawrence K Jung, MD Chief, Division of Pediatric Rheumatology, Children’s National Medical Center
Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, New York Academy of Sciences
Disclosure: Nothing to disclose.
Eyal Muscal, MD, MS Assistant Professor, Section of Pediatric Immunology, Allergy, and Rheumatology, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital
Disclosure: Nothing to disclose.
Sandy Craig, MD, Residency Program Director, Carolinas Medical Center; Associate Professor, Department of Emergency Medicine, University of North Carolina at Chapel Hill School of Medicine
Sandy Craig, MD is a member of the following societies; Alpha Omega Alpha and the Society for Academic Emergency Medicine.
Disclosure: Nothing to disclose.
Herbert S Diamond, MD Adjunct Professor of Medicine, Division of Rheumatology, University of Pittsburgh School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital
Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa
Disclosure: Merck Ownership interest Other; Smith Kline Ownership interest Other; Zimmer Ownership interest Other
Lance W Kreplick, MD, FAAEM, MMM Medical Director of Hyperbaric Medicine, Fawcett Wound Management and Hyperbaric Medicine; Consulting Staff in Occupational Health and Rehabilitation, Company Care Occupational Health Services; President and Chief Executive Officer, QED Medical Solutions, LLC
Disclosure: Nothing to disclose.
Barry L Myones, MD Associate Professor, Departments of Pediatrics and Immunology, Pediatric Rheumatology Section, Baylor College of Medicine; Director of Research, Pediatric Rheumatology Center, Texas Children’s Hospital
Barry L Myones, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American College of Rheumatology, American Heart Association, American Society for Microbiology, Clinical Immunology Society, and Texas Medical Association
Disclosure: Nothing to disclose.
Tom Scaletta, MD Chair, Department of Emergency Medicine, Edward Hospital; Past-President, American Academy of Emergency Medicine
Tom Scaletta, MD is a member of the following medical societies: American Academy of Emergency Medicine
Disclosure: Nothing to disclose.
Binita R Shah, MD, FAAP, Professor of Clinical Pediatrics and Emergency Medicine, SUNY Health Sciences Center at Brooklyn; Director of Pediatric Emergency Medicine, Departments of Emergency Medicine and Pediatrics, Kings County Hospital Center
Binita R Shah, MD, FAAPis a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Medscape Salary Employment
Renee Wilson, MD, Clinical Assistant Instructor, Department of Emergency Medicine, SUNY-Downstate and Kings County Hospital
Renee Wilson, MDis a member of the following medical societies: Society for Academic Emergency Medicine
Disclosure: Nothing to disclose
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.
Research & References of Rhabdomyolysis|A&C Accounting And Tax Services